Acemannan ameliorates STZ-activated diabetes by attenuating high glucose via inhibiting inflammatory cytokines and apoptosis pathway

Asma B Omer,Hisham N Altayb,Fahad A Al-Abbasi,Gaurav Gupta,Mohammed Muqtader Ahmed,Amira M Alghamdi,Sami I Alzarea,Nadeem Sayyed,Muhammad Shahid Nadeem,Imran Kazmi
DOI: https://doi.org/10.1016/j.ijbiomac.2023.127127
2023-12-31
Abstract:Acemannan, the main polysaccharide in Aloe vera, is a -(1, 4)-acetylated polymannose. According to numerous research findings, acemannan is a viable alternative for the treatment of pathological disorders. Streptozotocin (STZ, 60 mg/kg) administered intraperitoneally caused type 2 diabetes in rats. The current study sought to determine the anti-diabetic efficacy of acemannan (25 and 50 mg/kg) in STZ-injected rats. Different biochemical parameters including HbA1C, glucose and serum insulin, lipid profile, inflammatory markers, antioxidant, oxidative balance, liver function test, glycogen and creatinine, and caspase-3 were evaluated. In addition, a molecular docking study was performed to estimate acemannan's binding affinity to inflammatory markers. Acemannan may be a potent anti-diabetic agent for the treatment of diabetic patients, which will aid in future research into alternative diabetes medications.
What problem does this paper attempt to address?